Clinical trials with EdMeV and EdMeV-sodium iodide symporter (NIS) have been initiated at the Mayo Clinic and are being used to treat multiple myeloma, ovarian cancer, glioblastoma, pancreatic cancer, and medulloblastoma [200,201,202,203]. This evidence concerns the gene SLC5A5 and AL amyloidosis.